Spanish
A study on follicular lymphoma led by researchers at Memorial Sloan Kettering Cancer Center (MSK) showed that a combination of three agents presents promising efficacy for relapsed follicular lymphoma.
With the purpose of seeking new information and contributions to health, the study on follicular lymphoma showed that a combination of three drugs: rituximab (Rituxan®) and lenalidomide (Revlimid®), along with epcoritamab (Epkinly), works better than using the two drugs separately.
"These findings show a substantial benefit for patients. This combination of three drugs could become a new standard treatment for people with relapsed follicular lymphoma. New treatments like this are needed, as we currently have limited options for these patients," said Dr. Lorenzo Falchi, a lymphoma specialist at MSK, who led the study.
You can also read: Summit in Paris analyzes Ukraine's security in the face of a possible ceasefire
It should be noted that statistics reveal that this is the second most common non-Hodgkin lymphoma in Latin America and that, in addition, the median age of patients is between 60 and 62 in the region, slightly lower than the median of 65 years in the United States. According to the results, patients with follicular lymphoma showed a significantly greater response to treatment and a reduction of almost 80% in the risk of death or disease progression when they received epcoritamab in combination with the standard second-line regimen, compared to those treated with the standard regimen. Likewise, more than 95% of the patients who received the combination of the three drugs experienced a significant reduction in cancer, compared to 79% of those who received the standard treatment. Furthermore, more than 82% of the patients in the experimental group showed no traces of the disease after treatment, compared to 50% of the standard treatment group. At 16 months, 85% of the patients in the experimental group continued to show no signs of relapse, compared to only 40% of the standard treatment group.About Memorial Sloan Kettering Cancer Center (MSK)
People at Memorial Sloan Kettering Cancer Center (MSK) have a single mission: to eradicate cancer for life. Our specialized teams provide compassionate and expert personalized care to patients of all ages. Based on the fundamental research carried out at our Sloan Kettering Institute, MSK scientists collaborate to conduct innovative translational and clinical research that is revolutionizing the understanding of cancer as a disease and improving the ability to prevent, diagnose, and treat it. MSK is also dedicated to training the next generation of scientists and physicians, who continue the mission both at MSK and around the world. As MSK is one of the most recognized and dedicated comprehensive cancer centers, it has been recognized as one of the top two cancer hospitals in the country by U.S. News & World Report for over 30 years.
